ATC Group: L01EH03 Tucatinib

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01EH03 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01E Protein kinase inhibitors
4 L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
5 L01EH03

Active ingredients in L01EH03

Active Ingredient

Tucatinib is a tyrosine kinase inhibitor of HER2. It is used in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.

Related product monographs

Document Type Information Source  
 TUKYSA Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 TUKYSA Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)

United States medicines

Medicines classified under this ATC code globally

Austria (AT)

Canada (CA)

Croatia (HR)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Israel (IL)

Lithuania (LT)

Poland (PL)

Romania (RO)

Spain (ES)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.